Predicting in vivo activity of combination therapies from in vitro drug pairs in diverse environments.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36130481.
- Also identified by DOI 10.1016/j.xcrm.2022.100745 and PMC identifier 9512690.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
New antibiotic combinations are needed to improve the treatment of tuberculosis. Larkins-Ford and colleagues share a framework that combines in vitro pairwise drug response data and machine learning to rationally prioritize combinations for clinical development.<sup>1</sup>.
Medical subject headings
- Anti-Bacterial Agents
- Tuberculosis